Tag: Phase III Trial

Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in...

It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
eczema

Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms

Infants and young children finally get relief from eczema’s terrible itch
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Dupixent (dupilumab)

Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...

Majority of patients achieved histological disease remission in 16 weeks.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Atopic Dermatitis (Eczema)

Oral Medication Shows Strong Promise for Moderate to Severe Eczema in...

Upadacitinib yielded rapid and significant improvements in patients with moderate to severe atopic dermatitis in phase 3 trials.
Moderna Vaccine

FDA Authorizes Moderna Vaccine, Another Pfizer Vaccine Recipient Has Allergic Reaction

PEG compound possible culprit in allergic reactions.
Dupixent (dupilumab)

Dupixent (dupilumab) Study Shows Significant Improvement in Eosinophilic Esophagitis Signs and...

Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
Baby

Recruitment of Infants Begins for Phase 3 Trial of Cream to...

The trial needs 760 babies aged three weeks or younger whose parents or siblings suffer from either eczema, asthma or food allergies.